Kobayashi Pharmaceutical Co., Ltd. Q2 FY2026 Analysis: Profit Dip Masks Stable Core Sales Momentum
Kobayashi Pharmaceutical Co., Ltd. (TSE:4967), a leading manufacturer and seller of household goods that also diversifies into pharmaceuticals, medical devices, and health foods, reported mixed results for its second quarter (Q2) of the fiscal year ending December 2026. While Revenue remained robust at JPY 70.7bn (+2.5% YoY), profitability metrics saw significant contractions across the board, with Net Profit declining by -64.1% YoY to JPY 1.14bn.
| Metric | Current Period (JPY) | Prior Period (JPY) | YoY Change |
|---|---|---|---|
| Revenue | JPY 70.7bn | JPY 69.0bn | +2.5% |
| Operating Profit | JPY 2.16bn | JPY 6.65bn | -67.5% |
| Ordinary Income | JPY 3.01bn | JPY 7.25bn | -58.5% |
| Net Profit | JPY 1.14bn | JPY 3.17bn | -64.1% |
Kobayashi Pharmaceutical Co., Ltd. is a diversified consumer goods company, historically recognized for its air fresheners, but which has built out a substantial portfolio encompassing health supplements and personal care items.
Analysis of Quarterly Performance The steady increase in Revenue, driven by new product launches within domestic segments such as supplements and breath care, indicates resilient underlying demand for the company’s core consumer offerings. However, the sharp declines in Operating Profit (-67.5%) and Net Profit (-64.1%) suggest that cost management or extraordinary expenses significantly offset top-line growth during this quarter. The resulting Operating Margin of 3.1% points to structural pressure on profitability relative to historical performance.
Full-Year Guidance Management has provided a full-year forecast suggesting continued revenue expansion, though profit targets reflect expected margin stabilization rather than immediate recovery.
| Metric | Full-Year Forecast (JPY) | YoY Change |
|---|---|---|
| Revenue | JPY 173.0bn | +4.4% |
| Operating Profit | JPY 12.5bn | -16.2% |
| Ordinary Income | JPY 13.0bn | -23.5% |
| Net Profit | JPY 10.0bn | +173.5% |
The full-year guidance shows a notable divergence: while Revenue is expected to grow by +4.4% YoY, the forecast for Operating Profit and Ordinary Income suggests declines (-16.2% and -23.5%, respectively). Conversely, the Net Profit target of JPY 10.0bn implies an exceptionally strong rebound (+173.5% YoY), suggesting that this figure is heavily influenced by non-recurring items or significant changes in tax/provisioning expenses not reflected in core operational metrics. The revenue target: JPY 173.0bn (+4.4% YoY) appears to be a balanced projection against the current quarter’s volatility.
What to Watch Investors should closely monitor the trajectory of profitability relative to sales growth, as the significant profit compression seen in Q2 warrants deeper investigation into cost structures. Furthermore, while the Equity Ratio remains high at 82.9% (up from a previous ratio of 76.3%), indicating strong financial stability, the company must manage market perception regarding the large swings in Net Profit to avoid misinterpreting temporary charges as permanent operational headwinds. Finally, observing the execution of new product strategies across domestic segments will be key to confirming sustainable margin expansion moving into the second half of the fiscal year.
Source: Original filing (TDnet) | 日本語版
This article is for informational purposes only and does not constitute investment advice. Financial figures are AI-extracted and may contain errors — always verify against the original filing.